Compass Pathways PLC reports results for the quarter ended September 30 - Earnings Summary
Compass Pathways PLC reports results for the quarter ended September 30 - Earnings Summary
Compass Pathways PLC CMPS.OQ reported a quarterly adjusted loss of 7 cents per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of $-1.44. The mean expectation of fifteen analysts for the quarter was for a loss of 45 cents per share. Wall Street expected results to range from $-1.04 to -33 cents per share.
Reported revenue was zero; analysts expected zero.
Compass Pathways PLC's reported EPS for the quarter was a loss of 7 cents.
The company reported a quarterly loss of $9.83 million.
Compass Pathways PLC shares had fallen by 32.4% this quarter and gained 21.9% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 6% in the last three months.
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 18 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for Compass Pathways PLC is $20.00, about 58% above its last closing price of $8.41
This summary was machine generated from LSEG data November 3 at 02:32 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
Sep. 30 2026 | -0.45 | -0.07 | Beat |
Jun. 30 2026 | -0.40 | -1.88 | Missed |
Mar. 31 2026 | -0.38 | 0.71 | Beat |
Dec. 31 2025 | -0.39 | -1.00 | Missed |
Recent news on COMPASS Pathways
See all newsCompass Pathways PLC reports results for the quarter ended September 30 - Earnings Summary
Corrected: Compass Pathways Q3 net loss narrows on lower R&D charges
Corrected: BRIEF-COMPASS Pathways Q3 EPS USD -0.31
Psychedelic drug developers fall after Usona submits depressive drug application
Compass Pathways PLC expected to post a loss of 45 cents a share - Earnings Preview